Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York.…
Intelligent Bio Solutions Reports Record Fiscal First Quarter 2027 Revenue of $1.39 Million, Marking Sixth Consecutive Quarter of Year-Over-Year Growth
Intelligent Bio Solutions (NASDAQ: INBS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 59 employees.
The shares were at 1.390 USD on 20 November 2026, down 82.0% over 52 weeks. Its 52-week range is 1.350 USD to 24.90 USD: the price is 94.4% below the high and 3.0% above the low.
Its market capitalisation is 4.61M USD.
Intelligent Bio Solutions reports return on equity of -225.6%, an operating margin of -272.6% and revenue up 25.2% year over year.
It holds more cash than debt, a net cash position of 4.14M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.